Fiche traitement
Atezolizumab
National Cancer Institute (NCI) • Cancer
Suivi actif
Phase 3
Résumé
Atezolizumab est développé par National Cancer Institute (NCI). Le traitement est actuellement en Phase 3. Il est associé à Cancer. . Le statut actuel est : suivi actif.
À vérifier
Non renseigné
Phase 3
National Cancer Institute (NCI)
United States
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgical removal (resection) of stage I non-small cell lung cancer (NSCLC). Patients who have undergone resection for lung cancer are typically followed by observation or active surveillance, which involves closely watching a patient's condition but not giving treatment unless there are changes in test results. During active surveillance, patients are given certain exams and tests done on a regular schedule. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Atezolizumab and recombinant human hyaluronidase is a formulation of atezolizumab combined with an enzyme called hyaluronidase, which helps increase tissue absorption of the drug. Giving atezolizumab or atezolizumab and recombinant human hyaluronidase after resection may be effective for preventing NSCLC recurrence, and may be a better approach to treating patients with stage I NSCLC than the usual observation approach.
2026-09-10
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Phase 3
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Confiance automatique : 59%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : immune → Immunomodulation
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT07388524, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Contrôle de cohérence : 85/100
L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.
Transparence et qualité de la fiche
données vérifiablesClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-09-10
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréePhase 3
Études associées1
Publications associées14
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
18 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2026-07-10 | PublicationConsolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). | JAMA oncology |
| 2026-07-14 | PublicationAdvances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances. | Journal of drug targeting |
| 2026-07-14 | PublicationNrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma. | Nature communications |
| 2026-07-15 | PublicationPrognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab. | Annals of surgical oncology |
| 2026-07-15 | PublicationPerformance status 2 or higher in EMA labels for advanced non-small-cell lung cancer: a cross-sectional SmPC analysis. | Cancer treatment and research communications |
| 2026-07-18 | PublicationTransitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration. | Clinical pharmacokinetics |
| 2026-07-18 | PublicationMechanistic synergies and optimal sequencing of anti‑VEGF plus immune checkpoint inhibition in gastrointestinal cancers. | Discover oncology |
| 2026-07-22 | PublicationEfficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis. | Medical oncology (Northwood, London, England) |
| 2026-08-08 | PublicationTakotsubo syndrome in a cancer patient treated with a combination of anti-cancer drugs including immune checkpoint inhibitors: a case report. | European heart journal. Case reports |
| 2026-08-16 | Création de l’enregistrementNCT07388524 | Registre d’essai clinique |
| 2026-08-16 | PublicationInvestigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. | Clinical pharmacology and therapeutics |
| 2026-08-16 | PublicationLurbinectedin in the therapeutic landscape of SCLC: key clinical evidence and evolving role in the era of emerging therapies. | Critical reviews in oncology/hematology |
| 2026-08-16 | PublicationNeoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial. | International journal of cancer |
| 2026-08-16 | PublicationData mining methods, tasks, and algorithms for adverse drug reaction analysis in pharmacovigilance: A scoping review. | International journal of medical informatics |
| 2026-08-16 | PublicationCost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia. | Journal of medical economics |
| 2026-09-10 | Dernière mise à jour des donnéesAtezolizumab | Biomedical Watch |
| 2027-03-02 | Début de l’étudeNCT07388524 | Registre d’essai clinique |
| 2032-09-30 | Fin de l’étude prévue / enregistréeNCT07388524 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
1 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT07388524 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | Phase 3 | RECRUITING | United States | National Cancer Institute (NCI) |
Publications liées
14 publication(s)Publications liées
14 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS Trial. Voir source | 39707623 | 10.1002/cpt.3528 | Clinical pharmacology and therapeutics | |
| Lurbinectedin in the therapeutic landscape of SCLC: key clinical evidence and evolving role in the era of emerging therapies. Voir source | 42603642 | 10.1016/j.critrevonc.2026.105548 | Critical reviews in oncology/hematology | |
| Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial. Voir source | 42003237 | 10.1002/ijc.70508 | International journal of cancer | |
| Data mining methods, tasks, and algorithms for adverse drug reaction analysis in pharmacovigilance: A scoping review. Voir source | 42378892 | 10.1016/j.ijmedinf.2026.106554 | International journal of medical informatics | |
| Cost-effectiveness analysis of atezolizumab and bevacizumab as first-line systemic therapy in unresectable hepatocellular carcinoma in Malaysia. Voir source | 42033418 | 10.1080/13696998.2026.2658448 | Journal of medical economics | |
| Takotsubo syndrome in a cancer patient treated with a combination of anti-cancer drugs including immune checkpoint inhibitors: a case report. Voir source | 39104513 | 10.1093/ehjcr/ytae355 | European heart journal. Case reports | |
| Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis. Voir source | 42484760 | 10.1007/s12032-026-03343-1 | Medical oncology (Northwood, London, England) | |
| Transitioning Therapeutic Antibodies in Oncology from Intravenous to Hyaluronidase-Facilitated Subcutaneous Administration. Voir source | 42461495 | 10.1007/s40262-026-01669-7 | Clinical pharmacokinetics | |
| Mechanistic synergies and optimal sequencing of anti‑VEGF plus immune checkpoint inhibition in gastrointestinal cancers. Voir source | 42467392 | 10.1007/s12672-026-05539-3 | Discover oncology | |
| Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab. Voir source | 42448977 | 10.1245/s10434-026-20226-x | Annals of surgical oncology | |
| Performance status 2 or higher in EMA labels for advanced non-small-cell lung cancer: a cross-sectional SmPC analysis. Voir source | 42447750 | 10.1016/j.ctarc.2026.101313 | Cancer treatment and research communications | |
| Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances. Voir source | 40515614 | 10.1080/1061186X.2025.2520306 | Journal of drug targeting | |
| Nrf2-mediated metabolic reprogramming drives regulatory T cell accumulation in hepatocellular carcinoma. Voir source | 42443155 | 10.1038/s41467-026-73485-3 | Nature communications | |
| Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). Voir source | 42424047 | 10.1001/jamaoncol.2026.2330 | JAMA oncology |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-09-10
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.